Xiaoli Huang

Xiaoli Huang has a diverse background in the biotechnology and research fields. Beginning in 2016, they worked as a Postdoctoral Researcher at Lund University, focusing on investigating the function of galectin-3 in cancer cells using various techniques such as cell culture, flow cytometry, and western blot.

In 2018, Xiaoli joined Xintela AB as a Laboratory Engineer, where they conducted research and contributed to antibody drug conjugate projects. They designed different antibody drug conjugates, planned and carried out in vitro and in vivo assays, and were also responsible for humanizing antibodies.

While still at Xintela AB, Xiaoli transitioned to the role of Research Scientist and Project Leader in 2020. In this position, they continued to lead antibody drug conjugate projects, optimize efficacy in different cancer indications, and perform various in vitro assays.

In 2022, Xiaoli joined Targinta AB as a Senior Scientist and Project Manager. They drafted product development plans and led the antibody drug conjugate project, coordinating with different contract research organizations (CROs). Their responsibilities included target validation, in vitro and in vivo experiments, pharmacokinetic and toxicology studies, and CMC.

Currently, Xiaoli works at Asgard Therapeutics as a Project Director of Preclinical Pharmacology, beginning in 2022. The specific details of this role are not provided.

Xiaoli Huang completed their Bachelor's Degree in Biology at Shaanxi Normal University from 2004 to 2008. Following this, they pursued a Master's Degree in Cell/Cellular and Molecular Biology at Xiamen University from 2008 to 2011. Xiaoli further continued their education at Lund University, where they obtained their Doctor of Philosophy (Ph.D.) in Cell biology in breast cancer and drug discovery from 2011 to 2016.